Brief: Regulus Therapeutics Announces Strategic Prioritization Of Polycystic Kidney Disease Treatment

Regulus Therapeutics

12/10/2021 22:13

Oct 12 (Reuters) - Regulus Therapeutics Inc  RGLS.O :
    * REGULUS THERAPEUTICS ANNOUNCES STRATEGIC PRIORITIZATION OF
RGLS8429, ITS NEXT-GENERATION CANDIDATE FOR THE TREATMENT OF
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    * REGULUS THERAPEUTICS - WILL ADVANCE RGLS8429 SUPPORTED BY
STRONG
PRECLINICAL DATA AND SUPERIOR PHARMACOLOGIC PROFILE VERSUS
FIRST-GENERATION RGLS4326
    * REGULUS - VALIDATING SECTIONS OF IND-ENABLING TOXICITY
STUDIES
FOR RGLS8429 COMPLETED, WITH IND SUBMISSION, PHASE 1 INITIATION
EXPECTED IN Q2 2022
    * REGULUS THERAPEUTICS INC - FIRST-GENERATION RGLS4326 WILL
NOT BE
FURTHER ADVANCED BASED ON LIKELY LIMITATIONS ON DOSE AND
DURATION OF THERAPY
    * REGULUS THERAPEUTICS INC - EXPECTS TO HAVE A PRE-IND
MEETING
WITH FDA FOR RGLS8429 LATER THIS YEAR
    * REGULUS THERAPEUTICS INC - ANTICIPATES REPORTING TOP-LINE
BIOMARKER DATA IN FIRST COHORT OF RGLS8429 TREATED PATIENTS IN
EARLY 2023

Source text for Eikon:  ID:nPnbsH3Pwa 
Further company coverage:  RGLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))